For infection-associated cancer, the intactness of core elements in RIG-I and MDA5 signaling pathways may be taken into account to determine whether RIG-I or LGP2/MDA5 agonists are appropriate for the induction of anticancer immunity. The gene discussed is IFIH1; the disease is infection.